These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26264452)

  • 1. Liver transplant recipients and prioritization of anti-HCV therapy: an Italian cohort analysis.
    Lanini S; Nanni Costa A; Grossi PA; Procaccio F; Ricci A; Capobianchi MR; Terrault NA; Ippolito G
    Liver Int; 2016 Mar; 36(3):410-7. PubMed ID: 26264452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
    Lim KB; Sima HR; Fiel MI; Khaitova V; Doucette JT; Chernyiak M; Ahmad J; Bach N; Chang C; Grewal P; Kim-Schluger L; Liu L; Odin J; Perumalswami P; Florman SS; Schiano TD
    World J Gastroenterol; 2015 May; 21(20):6236-45. PubMed ID: 26034358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The corrected donor age for hepatitis C virus-infected liver transplant recipients.
    Dirchwolf M; Dodge JL; Gralla J; Bambha KM; Nydam T; Hung KW; Rosen HR; Feng S; Terrault NA; Biggins SW
    Liver Transpl; 2015 Aug; 21(8):1022-30. PubMed ID: 26074140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver Transplant From Increased-Risk Donors in the Era of Direct-Acting Antivirals for Hepatitis C.
    Shaikh OS; Rogal S; Malik A; Sharma V; Cacciarelli T
    Exp Clin Transplant; 2020 Oct; 18(5):605-611. PubMed ID: 31324136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Outcomes After Liver Transplantation Among Human Immunodeficiency Virus-Infected Recipients.
    Locke JE; Durand C; Reed RD; MacLennan PA; Mehta S; Massie A; Nellore A; DuBay D; Segev DL
    Transplantation; 2016 Jan; 100(1):141-6. PubMed ID: 26177090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver transplantation from anti-hepatitis C virus-positive donors: our experience.
    Álvaro E; Abradelo M; Fuertes A; Manrique A; Colina F; Alegre C; Calvo J; García M; García-Sesma A; Cambra F; Sanabria R; Moreno E; Jimenez C
    Transplant Proc; 2012; 44(6):1475-8. PubMed ID: 22841188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.
    Patel N; Bichoupan K; Ku L; Yalamanchili R; Harty A; Gardenier D; Ng M; Motamed D; Khaitova V; Bach N; Chang C; Grewal P; Bansal M; Agarwal R; Liu L; Im G; Leong J; Kim-Schluger L; Odin J; Ahmad J; Friedman S; Dieterich D; Schiano T; Perumalswami P; Branch A
    World J Gastroenterol; 2016 Mar; 22(9):2844-54. PubMed ID: 26973423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of hepatitis C infection before and after liver transplantation.
    Fagiuoli S; Ravasio R; Lucà MG; Baldan A; Pecere S; Vitale A; Pasulo L
    World J Gastroenterol; 2015 Apr; 21(15):4447-56. PubMed ID: 25914454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation.
    Gitto S; Belli LS; Vukotic R; Lorenzini S; Airoldi A; Cicero AF; Vangeli M; Brodosi L; Panno AM; Di Donato R; Cescon M; Grazi GL; De Carlis L; Pinna AD; Bernardi M; Andreone P
    World J Gastroenterol; 2015 Apr; 21(13):3912-20. PubMed ID: 25852276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Negativization of viremia prior to liver transplant reduces early allograft dysfunction in hepatitis C-positive recipients.
    Martini S; Tandoi F; Terzi di Bergamo L; Strona S; Lavezzo B; Sacco M; Maione F; Gonella F; Strignano P; Dell Olio D; Salizzoni M; Saracco GM; Romagnoli R
    Liver Transpl; 2017 Jul; 23(7):915-924. PubMed ID: 28422425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing repeat liver transplant graft utility through strategic matching of donor and recipient characteristics.
    Hung K; Gralla J; Dodge JL; Bambha KM; Dirchwolf M; Rosen HR; Biggins SW
    Liver Transpl; 2015 Nov; 21(11):1365-73. PubMed ID: 25865434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C: New challenges in liver transplantation.
    Filipec Kanizaj T; Kunac N
    World J Gastroenterol; 2015 May; 21(19):5768-77. PubMed ID: 26019441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients.
    Ueda Y; Uemoto S
    Transplantation; 2016 Jan; 100(1):54-60. PubMed ID: 26335914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal Changes and Regional Variation in Acceptance of Hepatitis C Virus-Viremic Livers.
    Mazur RD; Goldberg DS
    Liver Transpl; 2019 Dec; 25(12):1800-1810. PubMed ID: 31539195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents?
    Dall'Agata M; Gramenzi A; Biselli M; Bernardi M
    World J Gastroenterol; 2014 Jul; 20(28):9253-60. PubMed ID: 25071318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem.
    Grassi A; Ballardini G
    World J Gastroenterol; 2014 Aug; 20(32):11095-115. PubMed ID: 25170198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
    Shah AP; Cameron A; Singh P; Frank AM; Fenkel JM
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28060446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey.
    Shaffer AA; Thomas AG; Bowring MG; Van Pilsum Rasmussen SE; Cash A; Kucirka LM; Alqahtani SA; Gurakar A; Sulkowski MS; Cameron AM; Segev DL; Durand CM
    Transpl Infect Dis; 2018 Dec; 20(6):e12982. PubMed ID: 30144258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients.
    Avolio AW; Cillo U; Salizzoni M; De Carlis L; Colledan M; Gerunda GE; Mazzaferro V; Tisone G; Romagnoli R; Caccamo L; Rossi M; Vitale A; Cucchetti A; Lupo L; Gruttadauria S; Nicolotti N; Burra P; Gasbarrini A; Agnes S;
    Am J Transplant; 2011 Dec; 11(12):2724-36. PubMed ID: 21920017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.
    Vitale A; Spolverato G; Burra P; De Feo TM; Belli L; Donato F; Baroni GS; Marianelli T; Picciotto A; Toniutto P; Bhoori S; Passigato N; Lucà MG; Russo FP; Cillo U; Fagiuoli S;
    Transpl Int; 2015 Sep; 28(9):1055-65. PubMed ID: 25865602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.